AndhraNews.net
Home » Features » Health » Osteoarthritis

Osteoarthritis


About Osteoarthritis

Cartilage repair can improve quality of life of osteoarthritis patients

Osteoarthritis in News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Capstone Turbine Corporation of Class Action Lawsuit and Upcoming Deadline - CPST
Pomerantz LLP announces that a class action lawsuit has been filed against Capstone Turbine Corporation ("Capstone" or the "Company") (NASDAQ: CPST) and certain of its officers

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Galapagos creates new warrant plans
Mechelen, Belgium; 22 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 700,000 warrants under new warrant plans for the benefit of employees, directors and an independent consultant of the Company and its subsidiaries.

Galapagos receives transparency notification from Wellington Management Group LLP
Mechelen, Belgium; 22 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP.

GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES
Galapagos webcast presentation of the partnership to be held on 17 December, 17.00 CET/11 AM EST/8 AM PST, +1 646 254 3361 access code 5852445, more call number info further down

Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's disease
First JAK-inhibitor to show efficacy in Crohn's disease 48% clinical remission rate, statistically significant versus placebo after 10 weeks induction therapy Significant improvements in clinical response and IBDQ quality of life Filgotinib safety profile similar to that previously observed Webcast presentation of the results to be held tomorrow 8 December, 16

Galapagos increases share capital through warrant exercises
Mechelen, Belgium; 4 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises.

Canadian Football League Brings Attention to Player Health Through Multi-Year Marketing Partnership With Monovisc(R)
Editors Note: There is a photo associated with this press release.

Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015
Mechelen, Belgium; 20 November 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to a Special Shareholders' Meeting that will be held on Tuesday 22 December 2015 at 2:00 p.m. (CET) at the registered office of the Company.

Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier
Mechelen, Belgium; 20 November 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that GLPG1972, a first-in-class candidate drug aiming at treating osteoarthritis, has been dosed in a Phase 1 First-in-Human study

Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
Novartis International AG /Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
Novartis International AG /New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Horizon Pharma plc Announces Clinical Data to Be Presented at the 2015 ACR/ARHP Annual Meeting

The Cooper Institute Finds High Midlife Fitness and Cardiovascular Health Associated With Lower Healthcare Costs
For the first time, new research from The Cooper Institute, and partners including Vanderbilt University School of Medicine and the University of Texas Southwestern Medical Center, shows middle-aged adults who are healthy and fit have reduced healthcare spending later in life

Kalytera Appoints Stuart Silverman, MD to Scientific Advisory Board; Dr. Silverman Brings 40 Years' Expertise in Osteoporosis and Bone Healing
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid ("CBD") and synthetic CBD medicines that address the unmet needs of large patient populations, today announced that a leading international expert in osteoporosis and chronic pain, Stuart Silverman, MD, FACP, FACR, has joined its Scientific Advisory Board.

Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Novartis International AG /Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Orlando Cosmetic Dentist on Causes, Symptoms, and Treatments for TMJ Disorder
According to the National Institute of Dental and Craniofacial Research, approximately 5 to 12% of the population has temporomandibular joint disorder. Dr. Alfredo Gapuz, a dentist in Orlando, says TMJ Disorder -- also known as TMD -- can cause a number of debilitating symptoms and negatively impact the movement and function of the mouth, head, and neck. However, Dr

Blue Belt Technologies & Acibadem Healthcare Group Announces Formation of World-Class Orthopaedic Surgical Robotics Center and the First Clinical Navio Case Using the Smith & Nephew Journey Uni-Compartmental Knee System
ISTANBUL, TURKEY--(Marketwired - August 03, 2015) - Acibadem Healthcare Group, the leading healthcare services provider in Turkey, and Blue Belt Technologies announces the formation of an Orthopedic Surgical Robotics program as a leading global partner under Blue Belt Technologies' Center of Excellence program

Platelet-Rich Plasma Therapy: A Self-Healing Pain Management Phenomenon
Brooklyn rehabilitation and physical medicine facility, Physio Logic, offers pain management for chronic pain and injuries. With a strong emphasis on integrative medicine, Physio Logic practitioners evaluate the source of pain, learn the cause, and develop a unique treatment plan for each patient

Portea Medical Acquires MedybizPharma to Accelerate Penetration into India's Chronic Disease Market
Business Wire IndiaPortea Medical, India’s largest home healthcare company, today announced that it has acquired specialty pharmaceutical distributor MedybizPharma in a move that will enable Portea to strengthen patient engagement and provide better care for chronic disease patients in India.   The acquisition was made for an undisclosed consideration of cash and stock

First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis
Novartis International AG /First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Milestone Scientific Announces Distribution Agreement for Intra-Articular Instrument in China
LIVINGSTON, NJ--(Marketwired - December 22, 2014) - Milestone Scientific Inc

HC2's Subsidiary Pansend Has Founded GemDerm Aesthetics, Inc.
HC2 Holdings, Inc. ("HC2") (OTCQB: HCHC) announced today that Pansend, LLC, its indirect wholly owned subsidiary, has founded GemDerm Aesthetics, Inc., which has licensed technology created by scientists R. Rox Anderson, M.D., Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School; Dieter Manstein, M.D., Ph.D

Philip Falcone Departs Harbinger Group Inc. and Will Continue to Advance HC2 Holdings, Inc.
HC2 Holdings, Inc. ("HC2") (OTCQB: HCHC) announced today that Philip A. Falcone is resigning from his positions of Chief Executive Officer and Chairman of the Board of Directors of Harbinger Group Inc., effective December 1, 2014, and will be dedicating more of his time to HC2 Holdings, Inc. Mr

BeneVir Biopharm, Inc. Announces Investment From HC2's Subsidiary Pansend, LLC
BeneVir Biopharm, Inc., a biotechnology company developing a pipeline of cancer immunotherapies, today announced it closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (OTCQB: HCHC).

Axxess Pharma Receives Health Canada Approval to Sell High Potency Omega-3 Fish Oil Supplement Throughout Canada
Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have now received Health Canada approval to sell their high potency Omega-3 fish oil supplement throughout Canada

Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day

Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Novartis International AG /Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Novartis International AG /Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

HC2 Holdings, Inc. Announces the Pricing of Its $250,000,000 Senior Secured Notes Offering
HC2 Holdings, Inc. ("HC2" or the "Company") (OTCQB: HCHC) announced today the pricing of $250 million aggregate principal amount of 11.00% Senior Secured Notes due 2019 (the "Notes") being offered by the Company in a private offering (the "Offering") exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act")

Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.

Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Novartis International AG /Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

HC2 Holdings, Inc. Announces Launch of Its Senior Secured Notes Offering
HC2 Holdings, Inc. ("HC2" or the "Company") (OTCQB: HCHC) announced today an offering of $250 million aggregate principal amount of senior secured notes. The Company expects to use the net proceeds from the issuance of the notes to repay the outstanding amounts under its credit facility. The offering is subject to market conditions and other factors.

Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that DUEXIS® (ibuprofen/famotidine) has been selected as one of the winners of the 13th annual Chicago Innovation Awards. Last night at Chicago's Harris Theater, Timothy P

Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Novartis International AG /Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

HC2 Invests $5 Million in Series A-1 Financing Into NerVve Technologies to Accelerate Market Adoption of Market-Leading Visual Search Engine
HC2 Holdings, Inc. ("HC2") (OTCQB: HCHC) announced today the acquisition of a minority interest in NerVve Technologies through the purchase of $5 million in Series A-1 Preferred Stock.

Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc.
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the acquisition of the U.S. rights to PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) from Nuvo Research Inc. (Nuvo) for a one-time payment of $45 million in cash. PENNSAID 2% is approved in the U.S

HC2 Announces Final Results of Tender Offer for All Outstanding Shares of Schuff International, Inc.
HC2 Holdings, Inc. ("HC2") (OTCQB: HCHC) today announced the final results of its previously announced tender offer for all of the outstanding shares (the "Shares") of common stock of Schuff International, Inc. ("Schuff") that it does not already own (the "Offer"). HC2 has accepted for purchase 733,634 Shares at a price of $31

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Horizon Pharma plc (NASDAQ: HZNP) a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today that POZEN Inc. (NASDAQ: POZN), has received from the United States Patent and Trademark Office a Notice of Allowance for U.S

Galapagos half year revenues up 21%
·       Group revenues €77.4 M compared to €64.5 M in H1 2012·       Group net loss reduced to €5.4 M, from €11.3 M last year·       Cash position of €136

Galapagos delivers novel osteoarthritis molecules in alliance with Servier
Galapagos NV (Euronext: GLPG) announcedtodaythe achievement of a late stage discovery milestone for small moleculesagainsta novel target in the osteoarthritis (OA) alliance with Servier. Thismilestonetriggered a payment to Galapagos of EUR3 million and will contributeto Grouprevenues in the first half of 2013.

Kindred Bio Announces Closing of Initial Public Offering
Kindred Biosciences, Inc. (NASDAQ: KIN) (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its initial public offering of 8,625,000 shares of its common stock at an initial public offering price of $7

Kindred Bio Announces Exercise of Over-Allotment Option
Kindred Biosciences, Inc. (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the underwriters of its initial public offering exercised in full their option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price of $7.00 per share.

ZetrOZ, Inc. Awarded $397,000 NIH Grant
ZetrOZ, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $397,000 from The National Institute on Minority Health and Health Disparities of the U.S. National Institutes of Health to evaluate the effectiveness of its long-duration wearable ultrasound therapy technology for pain management in osteoarthritis

Kindred Bio Announces Pricing of Initial Public Offering
Kindred Biosciences, Inc. (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7

Kindred Bio Announces Launch of Initial Public Offering
Kindred Biosciences, Inc. (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share

Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement to acquire from AstraZeneca AB the U.S. rights to VIMOVO® (naproxen/esomeprazole magnesium) delayed-release tablets, further expanding Horizon's focus on key primary care physician targets in the U.S. VIMOVO is approved in the U.S

"Challenges of Treating Patients With Chronic Pain With Dysphagia (CPD): Physician and Patient Perspectives," Published in Peer-Reviewed Medical Journal
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of a research study in the peer-reviewed medical journal, Current Medical Research and Opinion. Two internationally recognized pain specialists, Dr. Joseph Pergolizzi, Jr. and Dr

BioElectronics Corporation: Letter to Shareholders
BioElectronics Corporation (OTC Pink: BIEL) presents letter to shareholders.

ABLYNX AND MERCK SERONO FURTHER STRENGTHEN THEIR COLLABORATION ON CO-DISCOVERY AND CO-DEVELOPMENT OF NANOBODIES
Creation of dedicated discovery unit at AblynxDiscovery and development of Nanobodies® against multiple targets in Merck Serono's core therapeutic areas

Horizon Pharma Announces Sanofi Compiegne as Additional Manufacturing Site for DUEXIS(R)
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United States Food and Drug Administration has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS® (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg)

Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into settlement and license agreements with Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc., to resolve pending patent litigation involving DUEXIS® (ibuprofen and famotidine) tablets.

Nicox First Half 2013 Financial Results and Business Update
Nicox S.A. (NYSE Euronext Paris: COX) today announced its financial results forthe six months ended June 30, 2013, and provided an update of itsactivities.

ABLYNX'S PARTNER INITIATES A PHASE I STUDY AND DOSES FIRST HEALTHY VOLUNTEER WITH ALX-0761
GHENT, Belgium, 21 June 2013 - Ablynx [Euronext Brussels: ABLX] today announced that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of the Nanobody®, ALX-0761, for the treatment of inflammatory diseases.

Health Enhancement Products, Inc. Receives Notice of Allowance From US Patent Office for Treatment of Disease Using Its Proprietary Algal Phyto-Percolate and Files Two New Patent Applications for Animal Health
Michigan-based natural products developer Health Enhancement Products (OTCBB: HEPI) was advised by the US Patent Office that a US patent will be issued for Application No. 12/067,735 regarding "Composition and Use of Phyto-Percolate for Treatment of Disease" thereby establishing its claims on novel methods of producing and administering products derived from its proprietary algal cultures

First US Patent for Vaccine Treatment of Dog and Cat Obesity Is Awarded to Braasch Biotech LLC
Braasch Biotech LLC, a biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced the company was assigned US Patent 8,425,914 for vaccination methods in the treatment of obesity in dogs and cats.

Ergoresearch Ltd (TSXV:ERG) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on InvestmentPitch.com
Vancouver, British Columbia, May 29, 2013 - Ergoresearch Ltd. (TSXV:ERG) was recently the subject of a StockPotentials report by Toronto-based eResearch Corporation. StockPotentials reports cover smaller companies that eResearch believes would be primarily of interest to retail investors.

Horizon Pharma Announces Receipt of Fifth U.S. Patent Allowance for DUEXIS(R)
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/620141 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS® (ibuprofen and famotidine) tablets

Mallinckrodt Pharmaceuticals Provides Financial Outlook for Fiscal Year 2014
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals business, today announced financial guidance for its fiscal year ending September 26, 2014.

Horizon Pharma to Receive Approval of DUEXIS(R) From the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA), based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization (MA) for DUEXIS® (ibuprofen/famotidine), pending review of updated licensing documents which the Company has provided to the MHRA

Houston Orthopedic and Sports Medicine Specialist Mark Sanders, M.D., Inducted Into the American Orthopaedic Society for Sports Medicine (AOSSM)
Dr. Mark Sanders joins an elite group of orthopedic and sports medicine specialists as he accepts membership into the American Orthopaedic Society for Sports Medicine (AOSSM).

Theravance Announces Initiation of Phase 2 Study With TD-9855 for the Treatment of Fibromyalgia
Theravance, Inc. (NASDAQ: THRX) announced today the initiation of a fibromyalgia Phase 2 study with TD-9855, the lead compound in Theravance's Monoamine Reuptake Inhibitor program

Total Knee Replacement Not Necessary in Many Cases
As the number of total knee replacements continues to grow in America, one Houston knee doctor says a total replacement is not necessary in many cases. Dr. Larry Likover, a leader in custom designed total knee replacement in Texas, says many people with osteoarthritis have only worn out one of three compartments in the knee. In those cases, the patient may only need a partial replacement.

Carbylan Biosurgery, Inc. and Shanghai Jingfeng Pharmaceutical Corporation Announce License Agreement
Carbylan Biosurgery, Inc. announced today that Shanghai Jingfeng Pharmaceutical Corporation (Jingfeng) has licensed rights to Carbylan's Hydros-TA technology and related products for the Greater China territory.

Aquentium Announces Plans to Open Laser Therapy Clinics
Aquentium, Inc. (OTCQB: AQNM) announced today that the company is planning on opening laser therapy clinics throughout the United States utilizing a new patented advanced low level laser therapy for individuals suffering from pain.

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking
Addex Therapeutics /Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model ofAlcoholBinge Drinking. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Ossur Hf : Clinical results demonstrate that the Unloader One reduces pain, increases function and life quality for knee osteoarthritis patients
 

Ablynx and Its Partner Advance Nanobody Candidate ALX-0751 in Pre-Clinical Development
Ablynx [Euronext Brussels: ABLX] todayannounced that they have advanced the Nanobody(®) candidate ALX-0751,togetherwith Merck Serono, a division of Merck KGaA, Darmstadt, Germany, intopre-clinical development in the field of oncology

ABLYNX AND ITS PARTNER ADVANCE NANOBODY CANDIDATE ALX-0751 IN PRE-CLINICAL DEVELOPMENT
GHENT, Belgium, 20 September 2012 - Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody® candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology

MorphoSys and the University of Melbourne Publish Preclinical Data on the Role of GM-CSF in Inflammatory, Arthritic and Osteoarthritic Pain
MorphoSys AG /MorphoSys and the University of Melbourne Publish Preclinical Data on theRoleof GM-CSF in Inflammatory, Arthritic and Osteoarthritic Pain. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

PropThink: Nuvo Research Gaining visibility; New Patent for Pennsaid 2% is Positive
Nuvo Research Inc. (TSX:NRI) announced that it obtained an additional U.S. patent for Pennsaid 2%, an improved follow-on formulation of its currently marketed Pennsaid product. Pennsaid contains the anti-inflammatory drug diclofenac, which is applied on the skin for pain conditions such as osteoarthritis of the knee

024 Pain Management System Celebrates New Arthritis Research
Patients with chronic inflammatory diseases, such as arthritis, are no stranger to pain. Although arthritis affects millions of Americans, especially those in older demographics, researchers have not yet found a cure for this elusive condition

Healthcare Review: Genworth & Laboratory Corp. Soars, Array Biopharma Slumps On News
U.S. Stocks were trading mostly higher on Wednesday in cautious trading following mixed economic data did little to change views of the Federal Reserve's policy decision in the afternoon, with the central bank seen as likely to leave the door open to further stimulus. Several healthcare stocks are making notable news at mid day on Wednesday.Array Biopharma Inc

NicOx first half 2012 financial results
NicOx S.A. (EURONEXT: COX)(PARIS: COX) today reports financial results for thesix months ended June 30, 2012, and provided an update on its activities.

Galapagos Delivers Candidate Drug in Osteoarthritis Alliance With Servier
- Galapagos NV (EURONEXT BRUSSELS: GLPG)announced todaythat it has identified the first pre-clinical candidate compound initsosteoarthritis alliance with Servier. The compound inhibits a novelmechanismof action discovered by Galapagos. This achievement triggered anundisclosedmilestone payment to Galapagos.

024 Pain Management System Offers Relief for Fibromyalgia and Related Symptoms
After osteoarthritis, fibromyalgia is the most prevalent musculoskeletal condition and is responsible for a wide range of unbearable symptoms in those who suffer from the condition. For example, many fibromyalgia patients experience various and widespread joint and muscle pain, ongoing fatigue and depression

Horizon Pharma Moving Ahead of FDA Decision
By Brian Wilson, ContributorShares of the pain drug developer Horizon Pharma (NASDAQ:HZNP) have recently seen some huge moves to the upside as the FDA's decision looms for the company's rheumatoid arthritis treatment RAYOS gets closer. Even after a virtual doubling of the shares since June, the company is valued at modest $265 million

Gene breakthrough gives new hope to millions of osteoarthritis sufferers
Scientists have discovered eight new genes that put people at risk of developing osteoarthritis, a crippling disease that affects eight million people.

Low calorie diet could help arthritis sufferers
A simple diet, which is very low on calorie and high in protein combined with regular exercise, could end the misery of arthritis for millions of sufferers, according to new research.

63pc women complain of knee pain
More than half of middle-aged and mature women suffer from knee pain, a new study has revealed.

Regular fish oil decreases osteoarthritis pain
London, November 18 (ANI): Hard evidence has now been found that taking small amounts of fish oil daily reduces joint pain in osteoarthritis patients. London, November 18 (ANI): Hard evidence has now been found that taking small amounts of fish oil daily reduces joint pain in osteoarthritis patients.

Batavia Chiropractor Supports Local Food Pantry With Fundraiser
Dr. Jack D. Sharratt of Sharratt Chiropractic has announced that once again this year his practice will be raising money to support the work of a local food pantry. This year will be the 8th year that the practice has held a fundraiser for the food pantry

Horizon Pharma Announces Launch of DUEXIS(R) (Ibuprofen/Famotidine) 800 mg/26.6 mg in the United States
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that DUEXIS® (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg), is now available to U.S

Market Research Study Forecasts the Size of the Orthopedics Devices Market
MarketResearch.com, the leading source of market research, has announced the addition of the new report "Global Orthopedics Devices Market (2011 - 2016)" to their collection of Medical Devices industry analysis. For more information, visit http://www.marketresearch.com/MarketsandMarkets-v3719/Global-Orthopedics-Devices-6671607/

Entest BioMedical and RenovoCyte Begin Pilot Study of "Universal Donor" Stem Cell Treatment of Canine Osteoarthritis
Entest BioMedical Inc. (OTCQB: ENTB) (PINKSHEETS: ENTB) and RenovoCyte LLC today announced the treatment of the first canine patient of a 10 dog pilot study utilizing Canine Endometrial Regenerative Cells (CERC) licensed from Medistem Inc. (PINKSHEETS: MEDS) in the treatment of canine osteoarthritis. The procedure was performed at Entest's McDonald Animal Hospital in Santa Barbara (http://www

Horizon Pharma and Sanofi Announce FDA Approval of DUEXIS(R) Commercial Manufacturing Facility
Horizon Pharma, Inc. (NASDAQ: HZNP) and Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved the use of the sanofi-aventis Canada Inc. manufacturing site in Laval, Quebec to manufacture DUEXIS®, (ibuprofen/famotidine) a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). DUEXIS was approved by the FDA in April 2011

Engineered nose, ears, knees, shoulders come closer to reality
Engineering cartilage replacement using body's own cells shows promise to heal knees, shoulders, ears and noses damaged by osteoarthritis, sports injuries and accidents, a new study has suggested.

Implantable replacement cartilage offers hope to beat osteoarthritis
Engineering cartilage replacement using body's own cells shows promise to heal knees, shoulders, ears and noses damaged by osteoarthritis, sports injuries and accidents, a new study has suggested.

Soon, jab made from 'tummy fat' cells could halt arthritis
Dutch and French researchers have revealed that a revolutionary jab made from stem cells found in tummy fat could soon stop osteoarthritis in its tracks.

Comment on this story

Share